A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

NCT03836001 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Epidermolysis Bullosa

Interventions

DRUG: Serlopitant Tablet
DRUG: Placebo Oral Tablet

Sponsor

Stanford University

Collaborators

[object Object]
[object Object]